JP2022536412A - 「冷たい腫瘍」を標的とすることによるがんの治療方法 - Google Patents

「冷たい腫瘍」を標的とすることによるがんの治療方法 Download PDF

Info

Publication number
JP2022536412A
JP2022536412A JP2021573248A JP2021573248A JP2022536412A JP 2022536412 A JP2022536412 A JP 2022536412A JP 2021573248 A JP2021573248 A JP 2021573248A JP 2021573248 A JP2021573248 A JP 2021573248A JP 2022536412 A JP2022536412 A JP 2022536412A
Authority
JP
Japan
Prior art keywords
patient
cancer
tumor
gene expression
rcor2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536412A5 (https=
Inventor
フォックス，ブライアン
アロンチック，イーダ
チョウ，トレイシー
フィルバロフ，エレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2022536412A publication Critical patent/JP2022536412A/ja
Publication of JP2022536412A5 publication Critical patent/JP2022536412A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021573248A 2019-06-13 2020-06-12 「冷たい腫瘍」を標的とすることによるがんの治療方法 Pending JP2022536412A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861094P 2019-06-13 2019-06-13
US62/861,094 2019-06-13
PCT/US2020/037521 WO2020252331A1 (en) 2019-06-13 2020-06-12 Methods of treating cancer by targeting cold tumors

Publications (2)

Publication Number Publication Date
JP2022536412A true JP2022536412A (ja) 2022-08-16
JP2022536412A5 JP2022536412A5 (https=) 2023-06-12

Family

ID=73781074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573248A Pending JP2022536412A (ja) 2019-06-13 2020-06-12 「冷たい腫瘍」を標的とすることによるがんの治療方法

Country Status (10)

Country Link
US (1) US12357633B2 (https=)
EP (1) EP3983016A4 (https=)
JP (1) JP2022536412A (https=)
KR (1) KR20220024426A (https=)
CN (1) CN115135324A (https=)
AU (1) AU2020290508A1 (https=)
CA (1) CA3143030A1 (https=)
IL (1) IL288939A (https=)
MX (1) MX2021015447A (https=)
WO (1) WO2020252331A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4114398A1 (en) * 2020-03-06 2023-01-11 Celgene Quanticel Research, Inc. Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
CN113421613B (zh) * 2021-06-08 2024-06-18 吴安华 一种基于铁死亡水平评价胶质母细胞瘤患者免疫治疗反应性的系统及分析方法
AU2024337882A1 (en) * 2023-09-07 2026-02-19 Sutter Bay Hospitals Co-targeting ncoa3 and pd-1 for cancer therapy
CN117538544A (zh) * 2023-11-22 2024-02-09 湛江中心人民医院 检测基因Ccdc181表达量的试剂在制备精子异常诊断产品中的应用
KR20250143182A (ko) * 2024-03-21 2025-10-01 차의과학대학교 산학협력단 시스플라틴에 대한 반응성의 예후를 나타내는 비소세포폐암 환자의 분류를 위한 분석방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079670A1 (en) * 2015-11-05 2017-05-11 Celgene Quanticel Research, Inc. Compositions comprising an inhibitor of lysine specific demethylase-1
WO2018031658A1 (en) * 2016-08-10 2018-02-15 Celgene Corporation Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
WO2019083971A1 (en) * 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160116474A1 (en) * 2013-06-20 2016-04-28 The Broad Institute, Inc. Compositions and methods for detecting and treating glioblastoma
KR102400920B1 (ko) 2014-05-01 2022-05-20 셀젠 콴티셀 리서치, 인크. 리신 특이적 데메틸라제-1의 억제제
US11998540B2 (en) * 2015-12-11 2024-06-04 The General Hospital Corporation Compositions and methods for treating drug-tolerant glioblastoma
MA51507A (fr) * 2016-12-09 2020-11-11 Constellation Pharmaceuticals Inc Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079670A1 (en) * 2015-11-05 2017-05-11 Celgene Quanticel Research, Inc. Compositions comprising an inhibitor of lysine specific demethylase-1
WO2018031658A1 (en) * 2016-08-10 2018-02-15 Celgene Corporation Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
WO2019083971A1 (en) * 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BARBARA MAJELLO ET AL.: ""Expanding the Role of the Histone Lysine-Specific Demethylase LSD1 in Cancer"", CANCERS, vol. Vol.11, 324, JPN6024025551, 7 March 2019 (2019-03-07), pages 1 - 15, ISSN: 0005360835 *
DAVID VAN MATER ET AL.: ""Management of recurrent Ewing sarcoma: challenges and approaches"", ONCOTARGETS AND THERAPY, vol. 12, JPN6024025557, 27 March 2019 (2019-03-27), pages 2279 - 2288, XP055770993, ISSN: 0005360840, DOI: 10.2147/OTT.S170585 *
ILEANA S MAULDIN ET AL.: ""TLR2/6 agonists and IFNγ synergize to induce melanoma cells to produce T-cell recruiting chemokine", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. Vol.1(Suppl 1), JPN6024025556, 2013, pages 17, ISSN: 0005360839 *
KATIE STREICHER ET AL.: ""Gene expression analysis of tumor biopsies from a trial of durvalumab to identify subsets of NSCLC", JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.35，No.15_suppl, JPN6024025553, 2017, pages 3041, ISSN: 0005360837 *
ROBERT H. VONDERHEIDE: ""The Immune Revolution: A Case for Priming, Not Checkpoint"", CANCER CELL, vol. 33, JPN6024025554, 2018, pages 563 - 569, XP085376829, ISSN: 0005360838, DOI: 10.1016/j.ccell.2018.03.008 *
WANQIANG SHENG ET AL.: ""LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade"", CELL, vol. 174, JPN6024025552, 2018, pages 549 - 563, XP055616669, ISSN: 0005360836, DOI: 10.1016/j.cell.2018.05.052 *

Also Published As

Publication number Publication date
MX2021015447A (es) 2022-04-06
AU2020290508A1 (en) 2022-01-27
IL288939A (en) 2022-02-01
KR20220024426A (ko) 2022-03-03
US12357633B2 (en) 2025-07-15
CA3143030A1 (en) 2020-12-17
WO2020252331A1 (en) 2020-12-17
EP3983016A1 (en) 2022-04-20
US20220273654A1 (en) 2022-09-01
CN115135324A (zh) 2022-09-30
EP3983016A4 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
JP2022536412A (ja) 「冷たい腫瘍」を標的とすることによるがんの治療方法
US11760728B2 (en) Tead inhibitors and uses thereof
EP3200775B1 (en) Combination therapies
US20240254120A1 (en) Ep4 inhibitors and synthesis thereof
JP2021519771A (ja) 腫瘍を処置する方法
KR20180134347A (ko) 암의 진단 및 치료 방법
JP2022536412A5 (https=)
JP7418322B2 (ja) Ｄｌｂｃｌ患者サブグループのオビヌツズマブ治療
US20220185886A1 (en) Methods for identifying biomarkers to predict treatment response
US12183434B2 (en) Diagnostic and therapeutic methods for cancer
TW202114684A (zh) 增強癌症病患之抗腫瘤免疫之方法
CN106716131B (zh) Mdm2拮抗剂的癌症疗法的患者个性化方法
CA3097874A1 (en) Methods and systems for characterizing severe crohn's disease
WO2023114984A1 (en) Tead inhibitors and uses thereof
JP2022526960A (ja) 腫瘍を処置する方法
JP2026009991A (ja) ウイルス感染、炎症又は癌の処置におけるバイオマーカー及び使用
CN113260363A (zh) 格拉普兰特(grapiprant)单位剂型
US20240131032A1 (en) An activity-guided map of electrophile-cysteine interactions in primary human immune cells
CN115698717A (zh) 癌症的治疗和诊断方法
EP4677119A1 (en) Prognostic and therapeutic methods for non-small cell lung cancer
US12560609B2 (en) Biomarkers predictive of cancer cell response to ML329 or a derivative thereof
RU2813966C2 (ru) Способы лечения злокачественных опухолей с использованием ингибитора atr
HK40055955A (en) Diagnostic and therapeutic methods for cancer
HK40066138A (zh) 对携带egfr或her2外显子20插入的癌细胞具有抗肿瘤活性的化合物
EA049557B1 (ru) Составной биомаркер для терапии злокачественной опухоли

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241224